Table 1.
Clinical and demographic characteristics of the study groups.
| Immunized with BNT162b2 Vaccine | p-Value | |||
|---|---|---|---|---|
| Yes | No | |||
| without Prior COVID-19 n = 143 |
with Prior COVID-19 n = 100 |
with Prior COVID-19 n = 60 |
||
| Age (years), mean ± SD | 45 ± 12 | 41 ± 12 | 42 ± 11 | 0.06 |
| Sex, n (%) | ||||
| Male | 58 (41) | 42 (42) | 24 (40) | 0.962 |
| Female | 85 (59) | 58 (58) | 36 (60) | |
| Comorbidity, n (%) | ||||
| At least one comorbidity | 62 (43) | 70 (70) | 31 (52) | 0.0001 |
| Diabetes | 2 (1.4) | 2 (2) | 2 (3.3) | 0.66 |
| SAH | 8 (6) | 9 (9) | 4 (6.6) | 0.581 |
| Allergic diseases | 15 (10) | 20 (20) | 6 (10) | 0.089 |
| Dermatitis | 2 (1.4) | 12 (12) | 2 (3.3) | 0.001 |
| Overweight | 35 (24) | 27 (27) | 17 (28) | 0.793 |
| Positivity to antibodies, n (%) | ||||
| 1st dose | ||||
| IgM | 8 (5.6) | 10 (10) | 0.297 | |
| IgG | 128 (89.5) | 100 (100) | 0.0005 | |
| 2nd dose, n (%) | ||||
| IgM | 0 (0) | 0 (0) | - | - |
| IgG | 100 (100) | 100 (100) | - | 1.00 |
| Vitamin D intake (4000 IU/day), n (%) | 42 (29) | 32 (32) | 20 (33) | 0.812 |
SD, standard deviation. SAH, Systemic arterial hypertension. p-values were calculated by Fisher’s exact or ANOVA test.